Polar Capital’s Atara Biotherapeutics ATRA Stock Holding History

Polar Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,000	Closed	-$4.13M	–	263
2018 Q3	$4.13M	Hold	4,000	–	–	0.04%	225
2018 Q2	$3.67M	Buy	+4,000	New	+$4.3M	0.02%	229

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital's ATRA Position: Q4 2018 in Review

Polar Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2018, closing a stake of 4,000 shares — an estimated $4.13M sold.

Polar Capital first reported a position in ATRA in Q2 2018 and held it in 2 quarters. The position peaked at $4.13M in Q3 2018. 121 funds tracked by Wall St. Rank hold ATRA as of Q4 2018.

Polar Capital reported no remaining Atara Biotherapeutics position as of Q4 2018 after selling out during the quarter.
Polar Capital sold 4,000 Atara Biotherapeutics shares in Q4 2018, an estimated $4.13M.
Polar Capital first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 2 quarters.
Polar Capital's Atara Biotherapeutics position peaked at $4.13M in Q3 2018.
121 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2018.

Based on Polar Capital's 13F filing for Q4 2018, filed 14 Feb 2019.